• Something wrong with this record ?

MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis

JJ. van der Vis, A. Prasse, EA. Renzoni, CJW. Stock, C. Caliskan, TM. Maher, F. Bonella, R. Borie, B. Crestani, M. Petrek, WA. Wuyts, AE. Wind, PL. Molyneaux, JC. Grutters, CHM. van Moorsel

. 2023 ; 28 (5) : 455-464. [pub] 20221226

Language English Country Australia

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011637

BACKGROUND AND OBJECTIVE: The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients. METHODS: In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed. RESULTS: In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged <56 year, to 63% in patients aged >75. In IPF patients aged <56, the MUC5B minor allele was not associated with survival. In IPF patients aged ≥56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 × 10-12 ). CONCLUSION: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011637
003      
CZ-PrNML
005      
20230801133219.0
007      
ta
008      
230718s2023 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/resp.14440 $2 doi
035    __
$a (PubMed)36571111
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a van der Vis, Joanne J $u St Antonius ILD Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands $u St Antonius ILD Center of Excellence, Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, the Netherlands $u European Reference Network (ERN) ILD core Network center $1 https://orcid.org/0000000267278416
245    10
$a MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis / $c JJ. van der Vis, A. Prasse, EA. Renzoni, CJW. Stock, C. Caliskan, TM. Maher, F. Bonella, R. Borie, B. Crestani, M. Petrek, WA. Wuyts, AE. Wind, PL. Molyneaux, JC. Grutters, CHM. van Moorsel
520    9_
$a BACKGROUND AND OBJECTIVE: The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients. METHODS: In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed. RESULTS: In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged <56 year, to 63% in patients aged >75. In IPF patients aged <56, the MUC5B minor allele was not associated with survival. In IPF patients aged ≥56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 × 10-12 ). CONCLUSION: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    12
$a idiopatická plicní fibróza $x genetika $7 D054990
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a genotyp $7 D005838
650    _2
$a alely $7 D000483
650    _2
$a mucin 5B $x genetika $7 D055257
650    _2
$a genetická predispozice k nemoci $7 D020022
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Prasse, Antje $u European Reference Network (ERN) ILD core Network center $u Division of Pulmonology, Hannover Medical School & DZL BREATH, Hannover, Germany $u Fraunhofer Institute ITEM, Hannover, Germany
700    1_
$a Renzoni, Elisabetta A $u Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK $u Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK $1 https://orcid.org/000000021118797X
700    1_
$a Stock, Carmel J W $u Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK $u Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK $1 https://orcid.org/0000000340908761
700    1_
$a Caliskan, Canay $u European Reference Network (ERN) ILD core Network center $u Division of Pulmonology, Hannover Medical School & DZL BREATH, Hannover, Germany
700    1_
$a Maher, Toby M $u National Heart and Lung Institute, Imperial College London, London, UK $u Keck Medicine of University of Southern California, Los Angeles, California, USA $1 https://orcid.org/0000000171929149
700    1_
$a Bonella, Francesco $u European Reference Network (ERN) ILD core Network center $u Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany $1 https://orcid.org/0000000175799767 $7 xx0274103
700    1_
$a Borie, Raphael $u European Reference Network (ERN) ILD core Network center $u Laboratoire d'excellence INFLAMEX, Inserm U1152, Paris, France $u Service de Pneumologie A, Hôpital Bichat, Paris, France $1 https://orcid.org/0000000299060024
700    1_
$a Crestani, Bruno $u European Reference Network (ERN) ILD core Network center $u Laboratoire d'excellence INFLAMEX, Inserm U1152, Paris, France $u Service de Pneumologie A, Hôpital Bichat, Paris, France
700    1_
$a Petrek, Martin $u University Hospital Olomouc - Experimental Medicine, Olomouc, Czech Republic $u Faculty of Medicine and Dentistry Palacky University - Pathophysiology, Molecular and Translational Medicine, Olomouc, Czech Republic
700    1_
$a Wuyts, Wim A $u European Reference Network (ERN) ILD core Network center $u Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals, Leuven, Belgium
700    1_
$a Wind, Anne E $u St Antonius ILD Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands $u European Reference Network (ERN) ILD core Network center
700    1_
$a Molyneaux, Philip L $u Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK $u National Heart and Lung Institute, Imperial College London, London, UK
700    1_
$a Grutters, Jan C $u St Antonius ILD Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands $u European Reference Network (ERN) ILD core Network center $u Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
700    1_
$a van Moorsel, Coline H M $u St Antonius ILD Center of Excellence, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands $u European Reference Network (ERN) ILD core Network center $u Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, the Netherlands
773    0_
$w MED00007218 $t Respirology (Carlton, Vic.) $x 1440-1843 $g Roč. 28, č. 5 (2023), s. 455-464
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36571111 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133216 $b ABA008
999    __
$a ok $b bmc $g 1963837 $s 1197902
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 28 $c 5 $d 455-464 $e 20221226 $i 1440-1843 $m Respirology $n Respirology $x MED00007218
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options